Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pan-cancer analysis of whole genomes

(2020)   NATURE

The evolutionary history of 2,658 cancers

(2020) Moritz Gerstung et al.   NATURE

JMJD6 cleaves MePCE to release positive transcription elongation factor b (P-TEFb) in higher eukaryotes

(2020) Schuyler Lee et al.   eLife

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

(2020) Kobe C. Yuen et al.   NATURE MEDICINE

Low‐dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo

(2020) Yuanfei Shi et al.   MOLECULAR CARCINOGENESIS

Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer

(2020) Antara Biswas et al.   BMC CANCER

The Intersection between Tumor Angiogenesis and Immune Suppression

(2019) Osama E. Rahma et al.   CLINICAL CANCER RESEARCH

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

(2019) Fiona M. Behan et al.   NATURE

JMJD6 modulates DNA damage response through downregulating H4K16ac independently of its enzymatic activity

(2019) Dawei Huo et al.   CELL DEATH AND DIFFERENTIATION

The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications

(2019) W. Marston Linehan et al.   Nature Reviews Urology

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma

(2019) Matthew Wong et al.   Nature Communications

Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities

(2019) Anna Brodziak et al.   Nature Reviews Urology

In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma

(2019) Fei Li et al.   Cancer Discovery

Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells

(2019) María G. Cortiguera et al.   Scientific Reports

Genetic and metabolic hallmarks of clear cell renal cell carcinoma

(2018) Danielle J. Sanchez et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

(2018) Robert J. Motzer et al.   EUROPEAN UROLOGY

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

(2018) Antoine Italiano et al.   LANCET ONCOLOGY

JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex

(2018) Wei-wei Gao et al.   MOLECULAR CELL

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

(2018) Arnaud Méjean et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

(2018) Christopher J. Ricketts et al.   Cell Reports

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors

(2018) Xun Huang et al.   CELL

Epidemiology of Renal Cell Carcinoma

(2018) Umberto Capitanio et al.   EUROPEAN UROLOGY

JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4

(2018) Junhu Wan et al.   INTERNATIONAL JOURNAL OF CANCER

Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis

(2018) Hye-Young Nam et al.   MOLECULAR CANCER RESEARCH

JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity

(2018) Yan Liu et al.   ONCOGENE

Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation

(2018) Ryan Raisner et al.   Cell Reports

Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib

(2018) Daniel J. Crona et al.   CANCER RESEARCH

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions

(2018) Aly-Khan A. Lalani et al.   EUROPEAN UROLOGY

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains

(2018) Jean-Philippe Lambert et al.   MOLECULAR CELL

A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer

(2018) Andrew Goodspeed et al.   EUROPEAN UROLOGY

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers

(2017) Maud Rijnders et al.   EUROPEAN UROLOGY

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas

(2017) Faizaan Mohammad et al.   NATURE MEDICINE

Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening

(2017) Julia Joung et al.   Nature Protocols

The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis

(2016) Olga Aprelikova et al.   Clinical Epigenetics

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

(2015) Michael Zengerle et al.   ACS Chemical Biology

Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis

(2015) Sidi Chen et al.   CELL

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

(2015) Pawel K Mazur et al.   NATURE MEDICINE

The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer

(2015) Lili Liao et al.   Cancer Genetics

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

JMJD6 Regulates ERα Methylation on Arginine

(2014) Coralie Poulard et al.   PLoS One

JMJD6 Promotes Colon Carcinogenesis through Negative Regulation of p53 by Hydroxylation

(2014) Feng Wang et al.   PLOS BIOLOGY

Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release

(2013) Wen Liu et al.   CELL

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer

(2009) J Mullenders et al.   ONCOGENE